Biglia, Luiza Vasconcelos 
; Felippini, A; Ribeiro, T. B; Lima, T. D. M; Aguiar, Patrícia Melo
Source: Value in Health. Conference titles: ISPOR Europe. Unidade: FCF
Subjects: DOENÇAS RARAS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIGLIA, Luiza Vasconcelos et al. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jval.2023.09.1783. Acesso em: 03 jun. 2024. , 2023APA
Biglia, L. V., Felippini, A., Ribeiro, T. B., Lima, T. D. M., & Aguiar, P. M. (2023). Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1016/j.jval.2023.09.1783NLM
Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783Vancouver
Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783
